- Article
A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application
- Jeffrey Roth,
- Cody J. Peer,
- Baskar Mannargudi,
- Helen Swaisland,
- Jung-Min Lee,
- Elise C. Kohn and
- William D. Figg
Olaparib (AZD2281) is an orally active PARP-1 inhibitor, primarily effective against cancers with BRCA1/2 mutations. It is currently in Phase III development and has previously been investigated in numerous clinical trials, both as a single agent an...

